Revolade® Receives EU Approval as First-in-Class Therapy for Patients with Severe Aplastic Anemia
FDA Expands Use of Promacta® to Include Treatment of Children Ages 1 and Older with Chronic Immune Thrombocytopenia
Matthew Korenberg to Join Ligand Pharmaceuticals as Chief Financial Officer
Ligand Reports Second Quarter 2015 Financial Results
Ligand Enters into Commercial License and Supply Agreement with Sanofi for Captisol-enabled SAR-125844
Revolade® Recommended by CHMP for EU Approval to Treat Patients with Severe Aplastic Anemia, a Serious Blood Disorder
Ligand to Report Second Quarter Results on August 4th
Ligand to Participate in Four Upcoming Investor Conferences
FDA Approves Promacta® for New Pediatric Chronic Immune Thrombocytopenia (cITP) Indication
